Clinical Trial Update: Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of Dovitinib (TKI258) in patients with castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Dovitinib (dovitinib)

Snippet

Sponsor: Korean Cancer Study Group | Conditions: Hormone Refractory Prostate Cancer | Phase 2 | Status: COMPLETED